Completed

Phase 4
Age: 16Years - 40Years
All Genders
ID00000374

Preventing Morbidity in First-Episode Schizophrenia

Led by Northwell Health · Updated on 2012-01-13

125

Participants Needed

2

Research Sites

N/A

Total Duration

On this page

Sponsors

N

Northwell Health

Lead Sponsor

N

National Institute of Mental Health (NIMH)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.

CONDITIONS

Official Title

Treatment for First-Episode Schizophrenia

Who Can Participate

Age: 16Years - 40Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • First episode schizophrenia, schizophreniform disorder or schizoaffective disorder
Not Eligible

You will not qualify if you...

  • Prior treatment with antipsychotic medications.

Trial Site Locations

Total: 2 locations

1

Hillside Hospital

Glen Oaks, New York, United States, 11004

Status Unknown

2

Bronx-Lebanon Hospital Center

The Bronx, New York, United States, 10456

Status Unknown

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months?

Juan A Gallego, Delbert G Robinson, Serge M Sevy...

https://pubmed.ncbi.nlm.nih.gov/21939612